Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Comment by tuesdaynightridon Jun 24, 2014 6:23pm
185 Views
Post# 22691158

RE:RE:Research summaries

RE:RE:Research summariesGreat post! You've read the same science that I have on how to destroy cancer cells. Chief among these is somehow employing oxygen to the site of the cancer. These PDC's sound as effective as any I've heard at getting oxygen to the cell nucleus before application of the laser light. I will review further the science that Theralase put out today if available.

With that said, there are now 6 to. 9 months before the start of the planned Ph1/2 trial per the Theralase timeline. My concern is that there will be a delay in trial start up unless additional funding is secured by the end of fall. The more publicity the better to achieve this funding.


Bullboard Posts